Complex I inhibition shifts mitochondrial dynamics and regulates cancer cell survival, providing a synthetic lethal interaction
Bhati, F. K.; Saha, U.; Singh, S.; Bhat, M. K.
Show abstract
Mitochondrial remodeling has emerged as a key regulator of cancer cell metabolism, cell stemness, development of drug resistance, and induction of apoptosis. Metformin, a clinically approved inhibitor of mitochondrial complex I, has shown variable antitumor activity in preclinical and clinical settings, implying that adaptive mitochondrial responses can buffer its cytotoxic effects. Here, we show that metformin reprograms mitochondrial dynamics in liver and colorectal cancer cells, increases mitochondrial biomass, alters fusion-fission balance, and enhances biogenesis in a cell type-dependent manner. These adaptations preserve mitochondrial function and support survival under metformin-induced energetic stress. Notably, the targeted disruption of these mitochondrial adaptations induces cell death in metformin-treated cancer cells and suppresses tumor growth. Overall, the study identifies metformin-driven mitochondrial remodeling as a central adaptive axis to complex I inhibition and provides a rationale for co-targeting mitochondrial dynamics and metabolism to enhance the anticancer efficacy of metformin.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Inhibition of mitochondrial dynamics preferentially targets pancreatic cancer cells with enhanced tumorigenic and invasive potential 96%
- Histone deacetylase inhibitor induces acetyl-CoA depletion leading to lethal metabolic stress in RAS-pathway activated cells 95%
- The MEK1/2 pathway as a therapeutic target in high-grade serous ovarian carcinoma 94%
Similar papers in this journal
- Tumor-associated macrophages confer resistance to chemotherapy (Trifluridine/Tipiracil) in digestive cancers by overexpressing Thymidine Phosphorylase 96%
- REDD1 is a determinant of the sensitivity of renal cell carcinoma cells to autophagy inhibition that can be therapeutically exploited by targeting PIM kinase activity 95%
- Biological activity of a stable 6-aryl-2-benzoyl-pyridine colchicine-binding site inhibitor, 60c, in metastatic, triple-negative breast cancer 94%
Similar papers in this journal
- Branched chain amino acid aminotransferase 2 Regulates Ferroptotic Cell Death in Cancer Cells 96%
- Targeting the mitochondrial RNA methyltransferase TRMT61B reveals new therapeutic opportunities in aneuploid cancer cells 95%
- The Second Mitochondrial Activator of Caspases (SMAC) regulates growth, inflammation and mitochondrial integrity in cancer cells 95%
Similar papers in this journal
- RASSF1A independence and early Galectin-1 upregulation in PIK3CA induced hepatocarcinogenesis: new therapeutic venues 94%
- PARP inhibition and pharmacological ascorbate demonstrate synergy in castration-resistant prostate cancer 94%
- Inhibition of Acyl-CoA Synthetase Long Chain Isozymes Decreases Multiple Myeloma Cell Proliferation and Causes Mitochondrial Dysfunction 94%